cialissx.com
89bio Announces Completion of Enrollment in ENLIVEN, the Phase 2b Trial of Pegozafermin for the Treatment of NASH219 total patients enrolled; topline data expected in the first quarter of 2023 | BioSpace
SAN FRANCISCO, 18 agosto 2022 (GLOBE NEWSWIRE) - 89bio, Inc.
Read More
Lucid Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results
NEW YORK--(BUSINESS WIRE)--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”),
Read More
89bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update | BioSpace
   - Reported positive topline results from ENTRIGUE Phase 2
Read More
89bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
   - Reported positive topline results from ENTRIGUE Phase 2
Read More
Nautilus, Inc. Reports Fiscal First Quarter 2023 Results
VANCOUVER, Wash.--(BUSINESS WIRE)--Aug 9, 2022--Nautilus, Inc. (NYSE: NLS) today reported
Read More
Nautilus, Inc. Reports Fiscal First Quarter 2023 Results
VANCOUVER, Wash.--(BUSINESS WIRE)--Nautilus, Inc. (NYSE: NLS) today reported its unaudited
Read More
Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress
Revolution Medicines, Inc.First two RAS(ON) Inhibitor drug candidates advance into
Read More
Blueprint Medicines Reports Second Quarter 2022 Results
-- Achieved $36.5 million in total revenues, including $28.5 million
Read More